US Stock MarketDetailed Quotes
IDXG Interpace Biosciences Inc
- 2.930
- -0.070-2.33%
15min DelayClose Oct 18 16:00 ET
12.82MMarket Cap16.28P/E (TTM)
3.000High2.680Low14.90KVolume2.900Open3.000Pre Close43.79KTurnover0.42%Turnover Ratio16.28P/E (Static)4.38MShares3.25052wk High-0.21P/B10.28MFloat Cap0.78052wk Low--Dividend TTM3.51MShs Float14200.000Historical High--Div YieldTTM10.67%Amplitude0.510Historical Low2.939Avg Price1Lot Size
Interpace Biosciences Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.21%12.04M | 4.55%10.27M | 26.31%40.21M | 23.42%10.28M | 10.86%9.08M | 49.10%11.03M | 24.02%9.83M | -3.86%31.84M | -8.55%8.33M | 1.64%8.19M |
| Operating revenue | 9.21%12.04M | 4.55%10.27M | 26.31%40.21M | 23.42%10.28M | 10.86%9.08M | 49.10%11.03M | 24.02%9.83M | -3.86%31.84M | -8.55%8.33M | 1.64%8.19M |
| Cost of revenue | 10.02%4.61M | 9.20%4.2M | 19.86%16.31M | 24.87%4.15M | 19.29%4.12M | 17.56%4.19M | 17.86%3.85M | -4.94%13.61M | -19.18%3.32M | -4.50%3.46M |
| Gross profit | 8.72%7.43M | 1.56%6.07M | 31.12%23.9M | 22.45%6.14M | 4.69%4.95M | 78.46%6.84M | 28.34%5.98M | -3.04%18.23M | 0.18%5.01M | 6.65%4.73M |
| Operating expense | -13.81%5.17M | -2.00%5.2M | -4.43%21.09M | -1.09%4.82M | -9.83%4.97M | -0.86%6M | -5.89%5.3M | -10.16%22.07M | -23.77%4.87M | -8.53%5.51M |
| Selling and administrative expenses | -8.57%5.03M | 4.63%5.06M | -2.50%19.6M | 3.62%4.64M | -7.62%4.62M | -0.63%5.5M | -4.92%4.84M | 1.09%20.1M | -19.54%4.48M | 4.01%5M |
| -Selling and marketing expense | 10.83%2.89M | 20.45%2.82M | 12.14%10.23M | 30.45%2.79M | 11.72%2.5M | 2.12%2.61M | 6.45%2.34M | -0.57%9.13M | -4.81%2.14M | -0.36%2.24M |
| -General and administrative expense | -26.02%2.14M | -10.22%2.24M | -14.67%9.36M | -20.92%1.85M | -23.24%2.12M | -2.98%2.89M | -13.58%2.49M | 2.50%10.97M | -29.52%2.34M | 7.83%2.77M |
| Research and development costs | -21.51%146K | -8.05%137K | -9.53%636K | 97.40%152K | -21.99%149K | -8.82%186K | -35.50%149K | -52.91%703K | -75.56%77K | -40.68%191K |
| Depreciation amortization depletion | --0 | --0 | -32.20%861K | -91.48%27K | -37.42%199K | 0.32%318K | 0.00%318K | -60.21%1.27M | -37.84%317K | -64.43%318K |
| -Depreciation and amortization | --0 | --0 | -32.20%861K | -91.48%27K | -37.42%199K | 0.32%318K | 0.00%318K | -60.21%1.27M | -37.84%317K | -64.43%318K |
| Operating profit | 171.27%2.26M | 29.48%874K | 173.20%2.81M | 829.58%1.32M | 97.95%-16K | 137.39%832K | 169.09%675K | 33.38%-3.84M | 110.25%142K | 50.91%-780K |
| Net non-operating interest income expense | 27.41%-188K | 16.92%-216K | 0.00%-1.01M | 11.70%-234K | 4.48%-256K | -48.85%-259K | 13.62%-260K | 3.08%-1.01M | 9.56%-265K | -4.28%-268K |
| Non-operating interest expense | -27.41%188K | -16.92%216K | 0.00%1.01M | -11.70%234K | -4.48%256K | 23.33%259K | -13.62%260K | -3.08%1.01M | -9.56%265K | 4.28%268K |
| Other net income (expense) | 140.80%71K | -531.58%-82K | 31.78%-674K | 79.20%-266K | -16.13%-252K | -150.00%-174K | -88.20%19K | -5.33%-988K | -1,404.71%-1.28M | -16.04%-217K |
| Special income (charges) | ---- | ---- | -103.14%-7K | 92.05%-7K | --0 | ---- | ---- | 139.89%223K | -131.32%-88K | --0 |
| -Less：Restructuring and merger&acquisition | ---- | ---- | 103.14%7K | -92.05%7K | --0 | ---- | ---- | -139.89%-223K | 131.32%88K | --0 |
| Other non- operating income (expenses) | 140.80%71K | -531.58%-82K | 44.92%-667K | 78.25%-259K | -16.13%-252K | -570.27%-174K | -88.20%19K | -219.53%-1.21M | -225.41%-1.19M | -542.86%-217K |
| Income before tax | 436.34%2.14M | 32.72%576K | 119.35%1.13M | 158.49%820K | 58.58%-524K | 119.45%399K | 138.85%434K | 24.62%-5.84M | 20.48%-1.4M | 37.78%-1.27M |
| Income tax | 0.00%4K | 0.00%4K | -41.38%17K | 0.00%5K | 136.36%4K | -75.00%4K | -77.78%4K | 104.11%29K | 123.81%5K | 98.46%-11K |
| Net income | 1,078.29%2.06M | 33.33%468K | 103.65%802K | 156.91%890K | 95.68%-614K | 104.44%175K | 115.62%351K | -46.95%-21.96M | 58.06%-1.56M | -298.99%-14.21M |
| Net income continuous Operations | 440.76%2.14M | 33.02%572K | 118.96%1.11M | 157.92%815K | 57.89%-528K | 119.11%395K | 137.89%430K | 16.65%-5.87M | 19.23%-1.41M | 4.93%-1.25M |
| Net income discontinuous operations | 66.36%-74K | -31.65%-104K | 98.07%-310K | 147.77%75K | 99.34%-86K | 88.25%-220K | 92.90%-79K | -103.55%-16.09M | 92.10%-157K | -477.79%-12.95M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 1,078.29%2.06M | 33.33%468K | 103.65%802K | 156.91%890K | 95.68%-614K | 104.44%175K | 115.62%351K | -46.95%-21.96M | 58.06%-1.56M | -298.99%-14.21M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 1,078.29%2.06M | 33.33%468K | 103.65%802K | 156.91%890K | 95.68%-614K | 104.44%175K | 115.62%351K | -46.95%-21.96M | 58.06%-1.56M | -298.99%-14.21M |
| Basic earnings per share | 1,075.00%0.47 | 37.50%0.11 | 103.67%0.19 | 156.76%0.21 | 104.30%0.04 | 115.09%0.08 | -43.49%-5.18 | 58.43%-0.37 | -294.12%-3.35 | |
| Diluted earnings per share | 1,075.00%0.47 | 37.50%0.11 | 103.47%0.18 | 154.05%0.2 | 104.30%0.04 | 115.09%0.08 | -43.49%-5.18 | 58.43%-0.37 | -294.12%-3.35 | |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
